ArticleFrontiers in microbiology2025
Broad-spectrum antimicrobial activity and
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structure-Activity Relationship Study of Antimicrobial Peptide with Cross-Kingdom Activity.Biochemistry · 2026Article
- Synthesis and antimicrobial activity of sulfonyl-imidazole linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridines:PEG-400 mediated one-pot reaction under ultrasonic irradiation.Frontiers in chemistry · 2026Article
- Discovery of a Novel Antimicrobial Peptide fromAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antimicrobial resistance (AMR) is a growing global health concern, necessitating the development of novel therapeutic agents. Antimicrobial peptides (AMPs) have emerged as promising candidates due to their broad-spectrum activity and lower resistance potential. SK1260 is a newly developed AMP evaluated for its efficacy against Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. Methods: The antimicrobial activity of SK1260 was assessed through minimum inhibitory concentration (MIC) assays against clinical and reference strains of Results: SK1260 exhibited potent antibacterial activity, with MIC values ranging from 3.13 to 12.5 µg/mL. Time-kill studies demonstrated dose- and time-dependent bactericidal effects, achieving complete bacterial clearance at concentrations ≥1× MIC, comparable to ciprofloxacin. In vivo studies revealed significant reductions in bacterial loads in vital organs, reduced histopathological damage, and improved survival in treated mice. Peptide treatment restored normal tissue architecture and showed efficacy equivalent to standard antibiotic therapy. Discussion: The study establishes SK1260 as a promising broad-spectrum antimicrobial agent with efficacy against drug-resistant pathogens. Its ability to reduce bacterial burden and protect tissue integrity in vivo highlights its therapeutic potential. Further preclinical development and clinical trials are warranted to explore SK1260 as a viable alternative in the fight against AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.